RU2014119919A - Способ лечения капиллярных гемангиом - Google Patents
Способ лечения капиллярных гемангиом Download PDFInfo
- Publication number
- RU2014119919A RU2014119919A RU2014119919/15A RU2014119919A RU2014119919A RU 2014119919 A RU2014119919 A RU 2014119919A RU 2014119919/15 A RU2014119919/15 A RU 2014119919/15A RU 2014119919 A RU2014119919 A RU 2014119919A RU 2014119919 A RU2014119919 A RU 2014119919A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- compounds
- salts
- brimonidine
- acceptable salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 26
- 150000003839 salts Chemical class 0.000 claims abstract 30
- 150000001875 compounds Chemical class 0.000 claims abstract 20
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims abstract 17
- -1 nerepinephrine Chemical compound 0.000 claims abstract 12
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims abstract 10
- KSRGADMGIRTXAF-UHFFFAOYSA-N a-Methyldopamine Chemical compound CC(N)CC1=CC=C(O)C(O)=C1 KSRGADMGIRTXAF-UHFFFAOYSA-N 0.000 claims abstract 10
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims abstract 9
- 229960003679 brimonidine Drugs 0.000 claims abstract 9
- 208000001969 capillary hemangioma Diseases 0.000 claims abstract 9
- 229960001528 oxymetazoline Drugs 0.000 claims abstract 9
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims abstract 5
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims abstract 5
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims abstract 5
- 229940025084 amphetamine Drugs 0.000 claims abstract 5
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 claims abstract 5
- 229960005209 lofexidine Drugs 0.000 claims abstract 5
- 229960005192 methoxamine Drugs 0.000 claims abstract 5
- 229960001344 methylphenidate Drugs 0.000 claims abstract 5
- 229960001802 phenylephrine Drugs 0.000 claims abstract 5
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims abstract 5
- 229960000833 xylometazoline Drugs 0.000 claims abstract 5
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims abstract 4
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 claims abstract 4
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 claims abstract 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960001724 brimonidine tartrate Drugs 0.000 claims abstract 4
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 claims abstract 4
- 229960004253 dexmedetomidine Drugs 0.000 claims abstract 4
- 229960004553 guanabenz Drugs 0.000 claims abstract 4
- 229960003938 moxonidine Drugs 0.000 claims abstract 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims abstract 3
- 229930182837 (R)-adrenaline Natural products 0.000 claims abstract 3
- 229960005139 epinephrine Drugs 0.000 claims abstract 3
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 claims 2
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical group Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims 2
- 241001116389 Aloe Species 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical class OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 235000011399 aloe vera Nutrition 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000000921 anthelmintic agent Substances 0.000 claims 1
- 229940124339 anthelmintic agent Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000002647 laser therapy Methods 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 230000000475 sunscreen effect Effects 0.000 claims 1
- 239000000516 sunscreening agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 abstract 1
- 229960002048 guanfacine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Optics & Photonics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Electromagnetism (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548838P | 2011-10-19 | 2011-10-19 | |
| US61/548,838 | 2011-10-19 | ||
| PCT/IB2012/002509 WO2013057580A1 (en) | 2011-10-19 | 2012-10-15 | Method for treating capillary hemangiomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014119919A true RU2014119919A (ru) | 2015-11-27 |
Family
ID=47630411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014119919/15A RU2014119919A (ru) | 2011-10-19 | 2012-10-15 | Способ лечения капиллярных гемангиом |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150044148A1 (enExample) |
| EP (1) | EP2768501A1 (enExample) |
| JP (1) | JP2014530847A (enExample) |
| KR (1) | KR20140091544A (enExample) |
| CN (1) | CN103889416A (enExample) |
| AU (1) | AU2012324544B2 (enExample) |
| BR (1) | BR112014009209A2 (enExample) |
| CA (1) | CA2850277A1 (enExample) |
| IL (1) | IL231821A0 (enExample) |
| MX (1) | MX2014004386A (enExample) |
| PH (1) | PH12014500785A1 (enExample) |
| RU (1) | RU2014119919A (enExample) |
| WO (1) | WO2013057580A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6188933B2 (ja) | 2013-10-07 | 2017-08-30 | テイコク ファーマ ユーエスエー インコーポレーテッド | 非鎮静量のデクスメデトミジンの経皮送達用方法及び組成物 |
| TWI645866B (zh) | 2013-10-07 | 2019-01-01 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| US20150098997A1 (en) | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions |
| RU2723761C1 (ru) | 2016-10-31 | 2020-06-17 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Способы устранения боли с использованием устройств для трансдермальной доставки дексмедетомидина |
| JP2023525664A (ja) * | 2020-04-21 | 2023-06-19 | ユニヴェルシテ カソリーク デ ルーヴァン | がんの処置のためのアルファ－２アドレナリン作動性受容体アゴニスト |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| CN1108565A (zh) * | 1994-10-21 | 1995-09-20 | 孙强 | 百草滴鼻液及其制备方法 |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| CN1391901A (zh) * | 2001-06-18 | 2003-01-22 | 赵培玲 | 治疗血管瘤的注射剂 |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20070082070A1 (en) * | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
| US8633181B2 (en) * | 2009-04-09 | 2014-01-21 | Rutgers, The State University Of New Jersey | Treatment of cutaneous hemangioma |
| CN101962404A (zh) * | 2010-06-17 | 2011-02-02 | 中国热带农业科学院热带生物技术研究所 | 一种用于治疗血管瘤的蛋白质 |
-
2012
- 2012-10-15 EP EP12820881.6A patent/EP2768501A1/en not_active Withdrawn
- 2012-10-15 RU RU2014119919/15A patent/RU2014119919A/ru not_active Application Discontinuation
- 2012-10-15 CN CN201280051518.7A patent/CN103889416A/zh active Pending
- 2012-10-15 US US14/344,091 patent/US20150044148A1/en not_active Abandoned
- 2012-10-15 KR KR1020147011913A patent/KR20140091544A/ko not_active Withdrawn
- 2012-10-15 AU AU2012324544A patent/AU2012324544B2/en not_active Ceased
- 2012-10-15 BR BR112014009209A patent/BR112014009209A2/pt not_active IP Right Cessation
- 2012-10-15 WO PCT/IB2012/002509 patent/WO2013057580A1/en not_active Ceased
- 2012-10-15 PH PH1/2014/500785A patent/PH12014500785A1/en unknown
- 2012-10-15 JP JP2014536350A patent/JP2014530847A/ja active Pending
- 2012-10-15 CA CA2850277A patent/CA2850277A1/en not_active Abandoned
- 2012-10-15 MX MX2014004386A patent/MX2014004386A/es unknown
-
2014
- 2014-03-31 IL IL231821A patent/IL231821A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2850277A1 (en) | 2013-04-25 |
| MX2014004386A (es) | 2014-11-12 |
| JP2014530847A (ja) | 2014-11-20 |
| AU2012324544A1 (en) | 2014-05-01 |
| US20150044148A1 (en) | 2015-02-12 |
| WO2013057580A1 (en) | 2013-04-25 |
| PH12014500785A1 (en) | 2014-05-12 |
| BR112014009209A2 (pt) | 2017-04-18 |
| KR20140091544A (ko) | 2014-07-21 |
| CN103889416A (zh) | 2014-06-25 |
| EP2768501A1 (en) | 2014-08-27 |
| AU2012324544B2 (en) | 2016-11-24 |
| IL231821A0 (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010313643B2 (en) | Methods of treating or preventing acute erythema | |
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| CA2780586C (en) | Combination therapy for treating or preventing an inflammatory skin disorder | |
| RU2014119919A (ru) | Способ лечения капиллярных гемангиом | |
| JP2013508454A5 (enExample) | ||
| RU2012122241A (ru) | Птеростилбен (pter) для применения в профилактике и/или лечении кожных заболеваний, повреждений или травм | |
| RU2012125249A (ru) | ПРИМЕНЕНИЕ АГОНИСТОВ α2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСОРИАЗА | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| BRPI1008727B8 (pt) | derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson | |
| RU2013125042A (ru) | Способ предотвращения или лечения опухоли кожи | |
| WO2012050831A3 (en) | Combination treatment for dermatological conditions | |
| BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
| MX345032B (es) | Antagonistas del receptor ep4 para el tratamiento de cáncer. | |
| RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
| RU2013110003A (ru) | Комбинация соединений для лечения или предотвращения кожных заболеваний | |
| RU2012134065A (ru) | Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления | |
| JP2014530847A5 (enExample) | ||
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| RU2013123043A (ru) | Гелевая композиция для местного применения | |
| RU2017101979A (ru) | Способ лечения ладонно-подошвенного синдрома и сопутствующих ему симптомов | |
| RU2014119879A (ru) | Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5 | |
| BR112013031201A2 (pt) | derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit | |
| BR112015019307A2 (pt) | derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada | |
| CO6660504A2 (es) | Agente terapeutico de liberacion sostenida para la hipertensión y la disfunción renal | |
| GEAP202316350A (en) | Treatments of prader-willi syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170314 |